Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)
- Conditions
- Interventions
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2016-06-29
- Target Recruit Count
- 60
- Registration Number
- NCT01787357
Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design
- Conditions
- Interventions
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 365
- Registration Number
- NCT01785186
- Locations
- 🇿🇦
The Aurum Institute for Health Research, Johannesburg, South Africa
🇿🇦University of Cape Town, Centre for Tuberculosis Research Innovation, Cape Town, South Africa
🇹🇿NIMR - Mbeya Medical Research Programme, Mbeya, Tanzania
A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2013-01-08
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT01762839
- Locations
- 🇺🇸
Spaulding Clinical, West Bend, Wisconsin, United States
A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin
- Conditions
- Interventions
- First Posted Date
- 2012-12-27
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT01756495
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
A Study Study to Investigate the Effect on QT/QTc Interval of Moxifloxacin After a Single Dose in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-12-27
- Last Posted Date
- 2016-04-26
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT01756521
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2012-12-25
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 860
- Registration Number
- NCT01756339
CP-690,550 Thorough QTc Study
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT01743677
- Locations
- 🇸🇬
Pfizer Clinical Research Unit, Singapore, Singapore
Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2014-11-14
- Target Recruit Count
- 74
- Registration Number
- NCT01674218
- Locations
- 🇺🇸
Quintiles Phase I Services - Overland Park, Overland Park, Kansas, United States
A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
- Target Recruit Count
- 345
- Registration Number
- NCT01658020
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Moxifloxacin_QT Study in Chinese Healthy Volunteer
- Conditions
- Interventions
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT01653990
- Locations
- 🇨🇳
Peking University Third Hospital Drug Clinical Trial Center, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.